Chimerix Inc

Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. The company's main compound, Brincidofovir is an investigational nucleoside analog that has antiviral activity in vitro against all five families of double-stranded deoxyribonucleic acid viruses that cause human disease. Potential indications for brincidofovir include prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), treatment of serious adenoviruses infection and disease, treatment of smallpox, and treatment of BK virus infection in kidney and HCT transplant recipients.
  • TickerCMRX
  • ISINUS16934W1062
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 29, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 20, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

1 director bought

A director at Chimerix Inc bought 18,000 shares at 3.600USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

ValuEngine Rating and Forecast Report for CMRX

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch